Target intelligence / Profile preview

Insulin-Insulin-like growth factor 2 readthrough transcript protein (INS-IGF2)

Target
INS-IGF2
Molecular classification
Other (chimeric transcript/protein; not a canonical receptor, enzyme, ion channel, transporter, etc.)
01

Overview

INS-IGF2 is a readthrough chimeric transcript joining the insulin (INS) gene on the 5′ end with the IGF2 gene on the 3′ end. The resulting protein shares the N-terminus with insulin and exhibits a unique, extended C-terminus derived from IGF2 noncoding exons, distinct from prepro-IGF2. Two transcript isoforms exist: one is predicted to encode a stable chimeric protein, while another is a candidate for nonsense-mediated decay. The locus is imprinted and paternally expressed in limb and eye tissues. INS-IGF2 expression is detectable in insulinomas, with evidence that it may be recognized by autoantibodies in type 1 diabetes, potentially enhancing insulin autoantigenicity. Its precise physiological and pathological roles remain unclear, and there is currently no evidence of use as a therapeutic target or as a target of known drugs.

Other names
Insulin, isoform 2INS-IGF2INS-IGF2 readthroughINSIGFInsulin-insulin-like growth factor 2 readthrough transcript proteinINS-IGF2 readthrough transcriptINS-IGF2 read-through productINSR2 Protein (GeneCards)
02

Biological functions

Possible hormone activity (Gene Ontology annotation)May participate in autoantigenicity in type 1 diabetesPrecise physiological function unknown at present
03

Disease associations

Diabetes (possible autoantigenic role in type 1 diabetes, hyperproinsulinemia, possible role in Maturity-Onset Diabetes of the Young type 10)
04

Biomarkers

Autoantibodies in diabetes mellitus type 1 may recognize INS-IGF2

Beyond the preview

Go deeper on Insulin-Insulin-like growth factor 2 readthrough transcript protein (INS-IGF2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Insulin-Insulin-like growth factor 2 readthrough transcript protein (INS-IGF2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call